Navigation Links
New research could pave the way to safer treatments for arthritis
Date:7/4/2013

The increased risk of heart attack or stroke associated with many arthritis drugs may be avoidable, according to a new international study co-authored by researchers at Imperial College London.

Drugs such as Vioxx, diclofenac, ibuprofen and Celebrex operate by blocking an enzyme known as COX-2, whose presence in blood vessels has up until now been held responsible for these side effects. New research carried out on mice has revealed that COX-2 is largely absent from the major blood vessels and instead found in the brain, gut, and kidney as well as the thymus gland in the chest.

Now that researchers know where in the body the drug is acting, they can begin to develop safer, more targeted drugs for patients with arthritis as well as cancer.

Arthritis drugs have long been associated with potentially fatal cardiovascular side-effects in patients. Health concerns led to the anti-inflammatory Vioxx being withdrawn from the market in 2004, and this week medical regulators have advised some patients to stop using the painkiller diclofenac.

Researchers have always believed that COX-2 was found in the blood vessels where it was central to preventing the formation of clots. This meant that any drug that inhibited the enzyme was thought to lead to an increased risk of clotting.

The new study, published today in the journal PLOS ONE, reveals that COX-2 is largely absent from the major blood vessels. Instead COX-2 appears to be present in the brain, kidney, thymus and gut, where it may well be affecting the cardiovascular health.

Lead author, Professor Jane Mitchell of Imperial's Faculty of Medicine said: "Now we know the true sites of COX-2, we can begin to develop new ideas that will lead to better drugs for arthritis and cancer with fewer side effects."

The new research suggests future development of COX-2 inhibitors that carry reduced risk of stroke or heart attack may be possible. Professor Mitchell
'/>"/>

Contact: Gilead Amit
gda07@imperial.ac.uk
Imperial College London
Source:Eurekalert

Page: 1 2

Related medicine news :

1. UCLA Brain Injury Research Center gets NCAA funding for research on sports concussions
2. NIH awards $20 million over 5 years to train next generation of global health researchers
3. Researchers develop a new cell and animal model of inflammatory breast cancer
4. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
5. Sexually abused boys at risk for more unsafe sex: UBC research
6. Researchers Find Gene Mutations That May Be a Key to Autism
7. LSUHSC research finds HPV-related head & neck cancers rising, highest in middle-aged white men
8. Researchers find evidence of banned antibiotics in poultry products
9. Presidential keynote address and new research highlights from the American Society of Pediatric Otolaryngology meeting
10. Scientific session and new research highlights
11. NJ stroke researchers report advances in spatial neglect research at AAN Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... of California, San Diego School of Medicine report that ... a recent major loss are more likely to be ... study is published in this month,s issue of the ... compassionate behaviors are associated with better health and well-being ... ways to improve the outcomes of individuals whose deficits ...
(Date:4/17/2014)... Jon McCullers, MD, was recently invited to submit ... Nature Reviews Microbiology , one of the world,s ... infectious disease specialist, and chair of the Department ... Science Center, analyzed the epidemiology and microbiology of ... as well as more recent 2009 novel H1N1 ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... offer a new way to detect and treat autism during ... months of life, when the brain is ... agree that,the earlier autism is diagnosed and therapy begun, the ... even when parents have an intuition,that "something is amiss" with ...
... Low Fat, Rich and Creamy Beverage ... FULLERTON, Calif., March 11 Wildwood Organics, a,division of ... today launched Probiotic Soymilk(TM). This delicious beverage is,certified organic, ... of soy protein per serving. Probiotic Soymilk(TM) is also ...
... a global,leader in dental and aesthetic lasers, today ... tissue lasers will receive a,tuition-free introductory laser certification ... dental laser education. The partnership is,the latest milestone ... education., "We fully recognize that training is ...
... and Phase II Trials, with Some Patients Already Past the Expected Median Average ... Survival Time for This Population -, - Data From Dosimetry Trial ... ... March 11 Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company developing ...
... March 10 As a longtime resident of Southern,Nevada, ... who have been,affected by this situation. I understand that ... against me and the Endoscopy Center of,Southern Nevada. While ... I,am unfortunately unable to do so at this time ...
... N.C., March 10 Cogdell Spencer,Inc. (NYSE: CSA ... 100,percent of the stock of Marshall Erdman and Associates. ... integrated healthcare real estate,company in the country, with over ... on January 23, 2008, was financed,through a $100 million ...
Cached Medicine News:Health News:Autism Awareness Month - New Hope for Detecting/Reversing Autism in Infants 2Health News:Wildwood Organics Introduces Probiotic Soymilk(TM) 2Health News:HOYA ConBio Partners With Advanced Laser Training to Offer Complementary Laser Certification Course in Dentistry 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 2Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 3Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 4Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 5Health News:Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials 6Health News:Cogdell Spencer Inc. Announces the Closing of the Marshall Erdman and Associates Merger 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Drug Delivery Systems -- Focus on End ... STUDY OBJECTIVES A drug ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... January 11, 2012 Simbionix USA Corporation, ... training, is pleased to announce that advanced virtual reality ... in addition to English. The new languages ... system, MentorLearn™. MentorLearn is available either as the new ...
... 11, 2012  Suneva Medical, a privately-held aesthetic medical device ... study to investigate the efficacy of Artefill for the ... being conducted at 10 centers throughout the U.S. and ... "Acne can have lasting effects on a patient,s ...
Cached Medicine Technology:Simbionix Comprehensive Medical Simulators now Available in Additional Languages 2Suneva Medical to Pursue Expanded Indications for Artefill® With Launch of Phase III Acne Scar Study 2
Standard knife with box, C profile...
... The Cryostage freezing stage is a refrigerated ... object holder, primarily for use with the 8000 ... other sledge microtomes. ,The refrigerated stage gives a ... the surface is ridged to provide good adhesion ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
... MNL 4404 & 4405 series Freezing Stages fit ... have no moving parts and need only the ... for operation. Freezing starts immediately and ... adjustable so that optimum cutting temperatures can be ...
Medicine Products: